翰宇药业晚间公告，公司收到美国食品药品监督管理局（FDA）确认，公司司美格鲁肽原料药获得DMF（Drug Master File）备案号040534。司美格鲁肽作为公司国际化布局的GLP-1类的多肽药物管线产品，本次获得DMF备案号，提高了公司在国际市场上的竞争力，取得DMF注册登记号的企业和其产品容易被客户优先考虑，为公司长期发展带来积极的影响。
Some counterfeits contain bacteria and have high impurity levels or different chemical structures to FDA-approved medicines.
Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...
9月25日，常山药业涨1.09%，成交额2.30亿元，换手率2.44%，总市值93.56亿元。 根据AI大模型测算常山药业后市走势。短期趋势看，连续3日被主力资金减仓。主力没有控盘。中期趋势方面，下方累积一定获利筹码。近期筹码减仓，但减仓程度减缓。舆情分析来看，目前市场情绪极度悲观。
9月25日，华东医药涨2.99%，成交额4.99亿元，换手率0.96%，总市值520.31亿元。 根据AI大模型测算华东医药后市走势。短期趋势看，连续3日被主力资金增仓。主力没有控盘。中期趋势方面，上方有一定套牢筹码积压。近期该股有吸筹现象，但吸筹力度不强。舆情分析来看，16家机构预测目标均价41.46，高于当前价39.78%。目前市场情绪极度悲观。 2、2023年7月7日公司互动：公司利拉鲁肽注 ...
来自MSN6 小时
扩产和接单热潮下，原料药押注多肽CDMO还有机会吗？GLP-1的“造富神话”，要瞄得准、跑得快才能抓住。 2000亿美元的“诱惑”难抵挡，市场集中原料药入局门槛高 Guide View ...
Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...
Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...
Large employers could spend as much as an additional 7.8% in health costs next year, according to a Business Group on Health survey.
From alcoholism to Parkinson’s, scientists are studying the mechanisms behind the broad clinical potential of weight-loss ...
U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...
U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈